Our Leadership

Management Team

Mahesh Kandula, Managing Director & CEO

Drug Design and Development, Innovation & IP

Mahesh brings over >16 years of scientific and entrepreneurial experience in the life science industry. Mr. Kandula has been named an inventor on 72 United States Issued Patents, 29 United States Patent Pending Applications and more than 181 International Patent Applications. Mr. Kandula received his Master of Technology degree from IIT Kharagpur.

Subbu Apparsundaram


Subbu Apparsundaram is an established scientist with extensive experience in drug discovery and development. Dr. Subbu founded VClinBio that entered into strategic partnership with Cellix Bio. Previously, Subbu was a Drug Discovery Scientist at Hoffmann-La Roche Pharmaceuticals, and a faculty at the University of Kentucky Medical Center. He has published several peer reviewed research papers.

Richard Minicus


Richard Minicus is a finance and business development professional with extensive M&A and venture capital investment experience focused on early-stage and established biomedical and life science companies. Rich worked at Becton Dickinson for 16 years in corporate development and venture capital investing and at Pfizer for five years in business development. Rich holds an MBA from Harvard Business School, and Master of Science in Biology from Fairleigh Dickinson University.

Bob Oliver

Executive Advisor

Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. Previously, Bob held senior level executive roles in Wyeth and Johnson & Johnson. Most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc.

Paul Jeffrey

Executive Consultant

Paul Jeffrey is an accomplished Pharmaceutical business consultant and leader with demonstrated new product development and business development capabilities. He has over 30 years of industry experience building product value by leading global teams and creating and implementing clinical and marketing programs to maximize commercial positioning and launch success. He has led commercial development team and alliance partnerships while at Pfizer as VP of Global Commercial Development group.

Scientific Team

Prabha Bhandari

CMC & Regulatory

Dr. Prabha Bhandari has more than 3 decades of professional leadership in Pharmaceutical Industry with expertise in Global API Regulatory Affairs including New Chemical Entities. She has rich experience in Corporate Quality Assurance at API Operations, Supervision of Global Regulatory Agencies’ audits (Viz. FDA US; EMA, Europe; TGA Australia; COFEPRIS Mexico; ANVISA Brazil; PMDA Japan etc), Data Reliability & Remediation and API Process Development in compliance with Global Regulatory requirements. She is Ph.D in Chemistry from Central Drug Research Institute, Lucknow, India and did Post-doctoral Research at Trinity College, Dublin, Ireland; University of Strathclyde, Glasgow, Scotland and University of Nottingham, England.

Ashok Rampal

Formulation development

Ashok Rampal has more than 3 decades of experience in R & D management, drug delivery and formulation development in renowned companies like Knoll Pharmaceuticals, Ranbaxy-Lilly, Ranbaxy Research Labs and Alkem Labs Ltd. Mr. Rampal holds Master’s degree in Pharmaceutics from Panjab University and Diploma in Business Management from Mumbai. He is inventor in more than 110 patent applications.

K B Sunil Kumar

Pre-Clinical development

Specialized in pharmaceutical toxicology and preclinical development with more than 25 years of professional experience in Drug Discovery and Development. Record of accomplishment of leading the planning, execution and authoring multiple successful Investigational New drug applications [INDs] in different therapeutic areas with global regulatory authorities. Dr. Sunil Kumar holds a Ph.D from University of Kerala, Thiruvananthapuram, Kerala, India.

Dr. Nilanjan Saha

Medical and Clinical Affairs

Dr. Nilanjan Saha is a medical research professional with expertise in new product evaluations, positioning of drugs in Therapy and ethical marketing. He is an active proponent of Antibiotic Stewardship. In the past, he has extensively involved in Volunteer studies with generic and NCEs; Phase I to III Clinical trials with anti-cancer and anti-malarial NCEs. His main interest is Clinical Development strategies for new Pharmaceutical products.

Sivanesan P

Pre-Clinical development

Sivanesan has > 12 years of experience in nonclinical development of various pharmaceutical products. Experienced in planning and conducting nonclinical studies for new chemical entities and evaluating the safety profile of a drug candidate in various therapeutic areas. He received bachelor degree in Veterinary Science and Master Degree in Veterinary pathology. He is also a certified Diplomate of American Board of Toxicology [DABT].

V.V.V. Satya Pratap

Project Manager

Valluri VV Satya Pratap has almost 12 years of pharmaceutical and biotech industrial experience. Prior to joining Cellix Bio, Mr. Satya Pratap served GVK BIO, Bioserve Biotechnology and Avigene as Scientific Manager. He holds a Masters Degree in Biotechnology from the University of Bangalore.